Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ASNB OTCMKTS:MDIT NASDAQ:NURO NASDAQ:NVIV OTCMKTS:RGIN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNBEKIMAS$2.09+10.0%$3.51$0.55▼$1.75$12.12M0.373,162 shs440 shsMDITCytoCore$0.00$0.00▼$0.00N/A87.281 shsN/ANURONeuroMetrix$4.55+4.4%$4.55$2.66▼$4.73$9.37M1.8216,958 shs35,522 shsNVIVInVivo Therapeutics$0.58$0.22▼$2.40$997K0.658.25 million shs1.89 million shsRGINRegenicin$0.00$0.00▼$0.00$20KN/A110,000 shsN/ABeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNBEKIMAS+10.00%+10.00%-44.27%-56.00%+161.25%MDITCytoCore0.00%0.00%0.00%0.00%0.00%NURONeuroMetrix0.00%0.00%0.00%+3.32%+23.31%NVIVInVivo Therapeutics0.00%0.00%0.00%0.00%0.00%RGINRegenicin0.00%0.00%0.00%0.00%-98.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASNBEKIMASN/AN/AN/AN/AN/AN/AN/AN/AMDITCytoCoreN/AN/AN/AN/AN/AN/AN/AN/ANURONeuroMetrixN/AN/AN/AN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARGINRegenicinN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNBEKIMAS 0.00N/AN/AN/AMDITCytoCore 0.00N/AN/AN/ANURONeuroMetrix 0.00N/AN/AN/ANVIVInVivo Therapeutics 0.00N/AN/AN/ARGINRegenicin 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNBEKIMASN/AN/AN/AN/A$0.03 per shareN/AMDITCytoCoreN/AN/AN/AN/AN/AN/ANURONeuroMetrix$3.03M3.09N/AN/A$13.18 per share0.35NVIVInVivo TherapeuticsN/AN/AN/AN/A$6.48 per shareN/ARGINRegenicinN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNBEKIMAS-$290KN/A0.00∞N/AN/A-7,902.31%-5,274.01%N/AMDITCytoCoreN/AN/A0.00N/AN/AN/AN/AN/AN/ANURONeuroMetrix-$6.53M-$4.59N/A∞N/A-203.71%-42.56%-39.26%8/4/2025 (Estimated)NVIVInVivo Therapeutics-$10.49MN/A0.00N/AN/AN/A-75.04%-65.01%N/ARGINRegenicin-$640KN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNBEKIMASN/AN/AN/AN/AN/AMDITCytoCoreN/AN/AN/AN/AN/ANURONeuroMetrixN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/ARGINRegenicinN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNBEKIMASN/A0.120.12MDITCytoCoreN/AN/AN/ANURONeuroMetrixN/A13.8812.70NVIVInVivo TherapeuticsN/A14.3014.30RGINRegenicinN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNBEKIMASN/AMDITCytoCoreN/ANURONeuroMetrix19.40%NVIVInVivo Therapeutics13.78%RGINRegenicin0.01%Insider OwnershipCompanyInsider OwnershipASNBEKIMAS7.80%MDITCytoCore85.40%NURONeuroMetrix7.30%NVIVInVivo Therapeutics2.45%RGINRegenicinN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNBEKIMAS115.80 million5.35 millionNot OptionableMDITCytoCore71N/AN/ANot OptionableNURONeuroMetrix202.06 million1.90 millionNot OptionableNVIVInVivo Therapeutics63.11 million3.03 millionNot OptionableRGINRegenicin3165.77 millionN/ANot OptionableNVIV, RGIN, ASNB, MDIT, and NURO HeadlinesRecent News About These CompaniesHistoryOctober 20, 2024 | npr.orgNShaun Micallef's Origin OdysseyOctober 18, 2024 | sbs.com.auSRegenicin, Inc. (RGIN)September 5, 2024 | finance.yahoo.comThe Cambridge World History of SlaveryAugust 20, 2024 | cambridge.orgCThe Cambridge Ancient HistoryAugust 3, 2024 | cambridge.orgCHow to watch State of Origin overseas: International broadcasters, TV channels, live streams, timesJuly 19, 2024 | sportingnews.comSState of Origin: When and where is Origin in 2024?May 21, 2024 | sportingnews.comSLGBT+ History Month - Teaching ResourcesMay 3, 2024 | bbc.co.ukHistory & TraditionApril 20, 2024 | smith.eduSSevere cold front hits central, eastern regions; schools forced to delay start of new semesterFebruary 21, 2024 | globaltimes.cnGPalworld map – all locations, regions, and points of interestFebruary 2, 2024 | pcgamesn.comPAlexander boys fend off top challenger in Region 5January 30, 2024 | ajc.comAJohn Kerry praises Biden for preventing 'uncontrolled war in many regions'January 19, 2024 | foxnews.comJournal of the History of Economic ThoughtJanuary 7, 2024 | cambridge.orgCHistory of computers: A brief timelineDecember 24, 2023 | livescience.comLWATCH: Blue Origin successfully launches rocket in first flight since 2022 crashDecember 21, 2023 | wlwt.comWBlue Origin successfully completes rocket mission more than a year after failed launchDecember 21, 2023 | nydailynews.comBlue Origin launches New Shepard rocket, aces landing in 1st return to flight since 2022 failure (video)December 20, 2023 | space.comSJeff Bezos’ Blue Origin puts a hold on its first suborbital space launch in 15 monthsDecember 20, 2023 | geekwire.comGHistory of Walmart: Timeline and FactsDecember 9, 2023 | thestreet.comMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhich Analyst-Favorite Drone Stock Will Come Out on Top?By Nathan Reiff | June 25, 2025View Which Analyst-Favorite Drone Stock Will Come Out on Top?3 Notable Stocks Just Split: Which One Could Be the Big Winner?By Leo Miller | June 26, 2025View 3 Notable Stocks Just Split: Which One Could Be the Big Winner?Top 3 Bank Stocks to Watch as Fed Rate Cuts LoomBy Chris Markoch | June 25, 2025View Top 3 Bank Stocks to Watch as Fed Rate Cuts LoomMore Than a Monetary Metal: Silver's Case for OutperformanceBy Jeffrey Neal Johnson | June 22, 2025View More Than a Monetary Metal: Silver's Case for OutperformanceCrowdStrike vs. Cloudflare: Which Cybersecurity Stock Wins?By Chris Markoch | July 11, 2025View CrowdStrike vs. Cloudflare: Which Cybersecurity Stock Wins?NVIV, RGIN, ASNB, MDIT, and NURO Company DescriptionsEKIMAS OTCMKTS:ASNB$2.09 +0.19 (+10.00%) As of 07/16/2025EKIMAS Corp. engages in the development of polymer materials, which provide characteristics in the design and development of medical devices. Its biomaterials are used in devices that are designed for treating a range of anatomical sites and disease states. The firm's products include ChronoFlex, ChronoSil, HydroMed, HydroThane, and PolyBlend. The company was founded in 1993 and is headquartered in Las Vegas, NV.CytoCore OTCMKTS:MDITMedite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida.NeuroMetrix NASDAQ:NURONeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.InVivo Therapeutics NASDAQ:NVIVInVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.Regenicin OTCMKTS:RGINRegenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
